DOCSLIB.ORG

Topically Applied Midodrine, 0.2%, an Α1-Agonist, for the Treatment Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Topically Applied Midodrine, 0.2%, an Α1-Agonist, for the Treatment Of Letters RESEARCH LETTER Table. Summary of Data for 12 Patients Characteristic No. (%) Topically Applied Midodrine, 0.2%, an α1-Agonist, for the Treatment of Erythromelalgia Age, mean (range), y 57 (26-79) We report the response of patients with erythromelalgia to topi- Female sex 9 (75) a cal midodrine hydrochloride, an α1-agonist. Erythromelalgia White race 11 (92) is a rare syndrome characterized by red, hot, painful feet and Pain level before medicationb hands, sometimes extending proximally. Episodes are gener- Severe 10 (83) ally intermittent, lasting from minutes to hours, but can be Moderate 1 (8) 1 continuous. Although numerous therapeutic regimens have Range of improvement (relief) 2 been described, none is universally effective. Since symp- Complete 0 toms are generally localized, topical treatments might be pref- Substantial 4 (33) 3-5 erable to avoid systemic adverse effects. Some 7 (58) Among the proposed mechanisms for erythromelalgia is None 1 (8) local vasodilatation since increased blood flow has been ob- Worsening of symptoms 0 served in Doppler studies. During symptoms, we have noted Adverse effects of midodrine hydrochloride, 2% that the mean temperature of the toe skin increased by 7.8°C, Nonspecific gastrointestinal tract discomfort 1 (8) and blood flow increased 10.2-fold.1,4 Increase in blood pressurec 1(8) Because vasodilatation may account for the flushing dur- Prior treatment ing an episode, the use of a vasoconstrictor seems reason- Gabapentin 4 (33) able. We hypothesized that midodrine, a vasoactive drug that Trazodone hydrochloride 1 (8) causes vasoconstriction, might be effective. Midodrine, a Combination gel amitriptyline, 2%, and ketamine, 0.5% 9 (75) peripherally acting α1-agonist, activates the α-adrenergic receptors of vessels, resulting in increased vascular tone and a The race/ethnicity of 1 patient (8%) was unknown. reduced blood volume. A patient with erythromelalgia b The level of pain was not documented for 1 patient (8%). responding to oral midodrine has been reported.6 c The increase was documented in 1 of 2 patients whose blood pressure was We used a topical preparation of midodrine for the man- measured consistently. agement of erythromelalgia. We then reviewed reported out- comes among patients with erythromelalgia who received was defined for the purposes of the study, and the data were treatment with topically applied midodrine, 0.2%. derived from interpretation of descriptions in the medical rec- ord of how patients reported responding to midodrine, 0.2%. Methods | This study was conducted from November 1, 2011, Further information was obtained from documentation of to November 1, 2013, and was approved by the Mayo Clinic follow-up visits to the department of dermatology after use of Institutional Review Board. Participants were patients in the midodrine, 0.2%. Blood pressure was monitored in 2 patients Department of Dermatology at Mayo Clinic in Rochester, before and after midodrine was prescribed. Minnesota, and provided written informed consent. The clini- cal diagnosis was erythromelalgia; midodrine, 0.2%, was to be Results | Topical midodrine, 0.2%, was prescribed for 12 pa- applied topically, and patients were available for follow-up. tients with erythromelalgia (Table). Most patients had re- Erythromelalgia was defined as the occurrence of red, hot, pain- ceived previously prescribed treatments with no substantial ful feet or hands. Midodrine, 0.2%, in a moisturizing skin cream improvement. Of the 2 patients whose blood pressure was (Vanicream) was compounded at the Mayo Clinic pharmacy and monitored before and after application of midodrine, 0.2%, pre- applied topically 3 times daily during symptoms. scription, 1 had no significant changes, but the other had an After the diagnosis was confirmed, data were abstracted increase in blood pressure. Ten patients (83%) responded to on demographics, adverse effects, and pain level before treat- therapy within minutes (not quantified). ment. Using a verbal rating scale, the patient chose words to describe the sensory qualities of the pain and the overall ex- Discussion | In this study, we summarized self-reported re- perience of the pain. Each word chosen was assigned a rank sponses to a topical preparation of midodrine, 0.2%, that was value and these values were used to determine the pain rat- used as needed. All but 1 patient reported improvement. Topi- ing index that ranges from 0 (no pain) to 5 (excruciating pain). cal midodrine, 0.2%, was well tolerated; only 2 of the 12 pa- Response to medication was graded as complete relief, sub- tients (17%) reported adverse effects. stantial relief (≥50% relief or marked relief), some relief (<50% This study had limitations. The sample with available relief), no change, or worsening of symptoms. The grading scale follow-up was small, available follow-up was documented in jamadermatology.com (Reprinted) JAMA Dermatology September 2015 Volume 151, Number 9 1025 Copyright 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 Letters the medical record but was not standardized, the follow-up multibacillary leprosy and recurrent ENL (recurrence 6 weeks criterion of interest was “general improvement” in erythro- after stopping treatment for ENL)3 or chronic ENL (lasting melalgia without obtaining further details, and many >24 weeks)2 were recruited after providing written informed patients were using other medications. Nonetheless, these consent. Patients who were pregnant, had comorbid condi- results suggest that a topical preparation of midodrine, 0.2%, tions, or were allergic to tetracyclines were excluded. is well tolerated and improves symptoms of erythromelalgia. All patients were corticosteroid dependent and did not re- Further investigation is warranted. spond to corticosteroid-sparing agents for almost 18 months, when used alone or in combination (clofazimine, 100 mg, Mark D. P. Davis, MD 3 times a day for 3 months; pentoxifylline, 800 mg, 3 times a Claudia S. Morr, MD day for 3 months; colchicine, 1.5 mg/d, for 3 months; azathio- Roger A. Warndahl, BS Pharm prine, 100-150 mg/d, for 3 months; and hydroxychloroquine, Paola Sandroni, MD, PhD 400 mg/d, for 6 months). Episodes of ENL generally recurred when the prednisolone dose was tapered below 40 mg. Author Affiliations: Department of Dermatology, Mayo Clinic, Rochester, Minocycline, 100 mg/d, was initiated for up to 3 months Minnesota (Davis, Morr); Pharmacy Services, Mayo Clinic, Rochester, Minnesota along with gradual tapering of the prednisolone regimen to dis- (Warndahl); Department of Neurology, Mayo Clinic, Rochester, Minnesota (Sandroni). continuation. No other concomitant drug was administered. Accepted for Publication: February 18, 2015. Baseline tests consisted of complete blood cell count, liver func- Corresponding Author: Mark D. P. Davis, MD, Department of Dermatology, tion, renal function, and antinuclear antibody, as well as chest Mayo Clinic, 200 First St SW, Rochester, MN 55905 ([email protected]). radiography and ultrasonography of the abdomen. The com- Published Online: May 6, 2015. doi:10.1001/jamadermatol.2015.0511. plete blood cell count, liver function tests, and renal function Author Contributions: Drs Davis and Morr had full access to all the data in the tests were subsequently repeated at 3 and 6 months. study and take responsibility for the integrity of the data and the accuracy of the data analysis. Results | The clinicoepidemiologic profile of the patients is in Study concept and design: Davis, Sandroni. Acquisition, analysis, or interpretation of data: Davis, Morr, Warndahl. the Table. All patients had a bacterial index greater than Drafting of the manuscript: Davis, Morr. 2 after successful completion of 1 year of World Health Critical revision of the manuscript for important intellectual content: Davis, Organization–recommended multidrug therapy for multibac- Warndahl, Sandroni. illary leprosy. Five patients had recurrent ENL, 4 had chronic Statistical analysis: Davis, Morr. Obtained funding: Davis. corticosteroid-dependent ENL, and 1 had chronic corticoste- Administrative, technical, or material support: Davis, Warndahl. roid- and thalidomide-dependent ENL. Four of the patients Study supervision: Davis, Sandroni. with chronic ENL had arthritis, 3 had acute neuritis, 2 had epi- Conflict of Interest Disclosures: None reported didymo-orchitis, and 1 had lymphadenitis. The prednisolone 1. Davis MD, Sandroni P, Rooke TW, Low PA. Erythromelalgia: vasculopathy, regimen was able to be tapered, without relapse, in 3 patients neuropathy, or both? a prospective study of vascular and neurophysiologic after 4 weeks of minocycline treatment and in 5 patients after studies in erythromelalgia. Arch Dermatol. 2003;139(10):1337-1343. 8 weeks of minocycline treatment. Prednisolone treatment was 2. Davis MD, O’Fallon WM, Rogers RS III, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol. stopped in these 8 patients after 16 to 18 weeks of tapering. Dur- 2000;136(3):330-336. ing 1 year of follow-up, only 2 patients had recurrence of mild 3. Kalava K, Roberts C, Adair JD, Raman V. Response of primary erythromelalgia ENL, which responded to rest and paracetamol (acetamino- to pregabalin therapy. J Clin Rheumatol. 2013;19(5):284-285. phen). On average, there was a decrease in the bacterial in- 4. Poterucha TJ, Weiss WT, Warndahl RA, et al. Topical amitriptyline combined dex by at least 1 log during 1 year of follow-up. Except for with ketamine for the treatment of erythromelalgia: a retrospective study of 36 hyperpigmentation (Figure), gastric pain (2 patients), vomit- patients at Mayo Clinic. J Drugs Dermatol. 2013;12(3):308-310. ing (1 patient), and mild transaminitis (1 patient), no other 5. Sandroni P, Davis MD. Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option? adverse effects were observed. Arch Dermatol. 2006;142(3):283-286. 6. Sakakibara R, Fukutake T, Kita K, Hattori T. Treatment of primary Discussion | Minocycline is a second-line antileprosy drug. erythromelalgia with cyproheptadine. J Auton Nerv Syst. 1996;58(1-2):121-122.
Load more

Recommended publications
  • Anti-Hypotensive Effects of M6434, an Orally Active a 1-Adrenoceptor Agonist, in Rats
    Anti-Hypotensive Effects of M6434, an Orally Active a 1-Adrenoceptor Agonist, in Rats Tatsuroh Dabasaki, Masato Shimojo, Hiroshi Ishikawa and Akio Uemura Fuji Central Research Laboratory, Mochida Pharmaceutical Co., Ltd., 722 Jimba-aza-Uenohara, Gotemba, Shizuoka 412, Japan Received December 19, 1991 Accepted February 17, 1992 ABSTRACT-The anti-hypotensive effects of M6434 were evaluated and compared with those of other orally active sympathomimetics in rats. Oral administration of M6434 (0.5-2.0 mg/kg) and midodrine (1.0 5.0 mg/kg) also produced a dose-related increase in mean arterial pressure in normotensive rats. The pressor effect of M6434 was about 4 times more potent than that of midodrine. Both M6434 and midodrine caused a dose-dependent decrease in heart rate. The pressor effect of M6434 (1.0 mg/kg) did not diminish after its repeated administration for 7 days. The pretreatment with M6434 (0.5 1.0 mg/kg) and midodrine (2.0 5.0 mg/kg) improved the orthostatic index in the experimental model of postural hypotension in rats. The effect of M6434 on postural hypotension was about 5 times more po tent than that of midodrine. Intravenously injected M6434 (3-300pg/kg) produced a dose-dependent increase in the blood pressure of pithed rats. These results suggest that M6434 possesses a potent anti hypotensive activity which is superior to that of midodrine, and M6434 may be useful in the treatment of essential and postural hypotension. Keywords: M6434, a 1-Agonist, Midodrine, Postural hypotension, Orthostatic index M6434, 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imida in clinical therapy.
    [Show full text]
  • Effectiveness of Midodrine Treatment in Patients with Recurrent Vasovagal
    Europace (2011) 13, 1639–1647 CLINICAL RESEARCH doi:10.1093/europace/eur200 Syncope and Implantable Loop Recorders Effectiveness of Midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial) Downloaded from Jacobus J.C.M. Romme1, Nynke van Dijk2, Ingeborg K. Go-Scho¨ n3,4, Johannes B. Reitsma1, and Wouter Wieling3* 1Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands; 2Department of General Practice/ Family Medicine, 3 4 Academic Medical Center, Amsterdam, The Netherlands; Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands; and Bmeye Cardiovascular http://europace.oxfordjournals.org/ Monitoring B.V., Academic Medical Center, Amsterdam, The Netherlands Received 26 January 2011; accepted after revision 2 June 2011; online publish-ahead-of-print 13 July 2011 Aims Initial treatment of vasovagal syncope (VVS) consists of advising adequate fluid and salt intake, regular exercise, and physical counterpressure manoeuvres. Despite this treatment, up to 30% of patients continue to experience regular episodes of VVS. We investigated whether additional Midodrine treatment is effective in these patients. ..................................................................................................................................................................................... Methods In our study, patients with at least three syncopal and/or severe pre-syncopal recurrences during non-pharmacologi- and results cal treatment were eligible to receive double-blind cross-over treatment starting either with Midodrine or placebo. at Universiteit van Amsterdam on November 15, 2011 Treatment periods lasted for 3 months with a wash-out period of 1 week in-between. At baseline and after each treatment period, we collected data about the recurrence of syncope and pre-syncope, side effects, and quality of life (QoL).
    [Show full text]
  • Drugs-Biologicals FORMULARY for INTERNET PAGE 12 26 18
    AVG ITEM Average Patient Item Charge Code Description BIL AWP /pkg COST Price 25000041 SODIUM and POTASSIUM BICARBONATE TBEF UD $3.61 $0.12 $1.00 25000054 GLIMEPIRIDE TAB 1 MG UD $8.25 $0.11 $1.30 25000086 amLODIPine TAB 5 MG UD $8.65 $0.06 $1.00 25000087 AMMONIA AROMATIC SOLN 15 % (W/V) UD $3.53 $0.17 $1.00 25000090 AMOXICILLIN CAP 500 MG UD $20.12 $0.19 $1.00 25000102 ABACAVIR TAB 300 MG UD $507.10 $8.45 $16.90 25000103 ACAMPROSATE TBEC 333 MG UD $182.38 $0.80 $1.76 25000104 ACARBOSE TAB 25 MG UD $16.70 $0.27 $1.00 25000106 ACETAMINOPHEN SUPP 120 MG UD $5.09 $0.42 $1.00 25000108 ACETAMINOPHEN SUPP 325 MG UD $4.91 $0.44 $1.00 25000109 ACETAMINOPHEN TAB 325 MG UD $12.39 $0.02 $1.00 25000111 ACETAMINOPHEN TAB 500 MG UD $2.34 $0.02 $1.00 25000112 ACETAMINOPHEN SUPP 650 MG UD $3.83 $0.17 $1.00 25000113 ACETAMINOPHEN SOLN 650 MG/20.3 ML UD $75.74 $0.48 $1.22 25000117 ACETAMINOPHEN-CODEINE TAB 300-30 MG UD $12.41 $0.09 $1.00 25000121 ACETYLCYSTEINE SOLN 200 MG/ML (20 %) UD $18.18 $7.66 $15.32 25000140 ALBUTEROL SULFATE NEBU 2.5MG/3ML (0.083 %) UD $8.58 $0.29 $1.00 25000147 ALLOPURINOL TAB 100 MG UD $18.45 $0.12 $1.00 25000150 ALPRAZolam TAB 0.25 MG UD $8.87 $0.09 $1.00 25000151 ALPRAZolam TAB 0.5 MG UD $4.16 $0.04 $1.00 25000182 AMIODARONE TAB 200 MG UD $15.70 $0.20 $1.00 25000184 AMITRIPTYLINE TAB 10 MG UD $8.73 $0.06 $1.00 25000186 AMITRIPTYLINE TAB 25 MG UD $17.46 $0.08 $1.00 25000188 AMITRIPTYLINE TAB 50 MG UD $34.90 $0.16 $1.00 25000205 HYDROCORTISONE ACETATE SUPP 25 MG UD $127.30 $5.75 $11.50 25000206 HEMORRHOIDAL SUPPOSITORY SUPP 0.25
    [Show full text]
  • Midodrine As Adjunctive Support for Treatment of Refractory Hypotension
    Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial) The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Anstey, Matthew H., Bradley Wibrow, Tharusan Thevathasan, Brigit Roberts, Khushi Chhangani, Pauline Yeung Ng, Alexander Levine, Alan DiBiasio, Todd Sarge, and Matthias Eikermann. 2017. “Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).” BMC Anesthesiology 17 (1): 47. doi:10.1186/s12871-017-0339-x. http://dx.doi.org/10.1186/ s12871-017-0339-x. Published Version doi:10.1186/s12871-017-0339-x Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32072012 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Anstey et al. BMC Anesthesiology (2017) 17:47 DOI 10.1186/s12871-017-0339-x STUDY PROTOCOL Open Access Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial) Matthew H. Anstey1,2, Bradley Wibrow1,2, Tharusan Thevathasan3, Brigit Roberts1, Khushi Chhangani3, Pauline Yeung Ng3, Alexander Levine4, Alan DiBiasio5, Todd Sarge6 and Matthias Eikermann3,7* Abstract Background: Patients admitted to intensive care units (ICU) are often treated with intravenous (IV) vasopressors.
    [Show full text]
  • Droxidopa (NORTHERA) Drug Monograph
    Droxidopa Drug Monograph Droxidopa (NORTHERA™) National Drug Monograph December 2014 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a comprehensive drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information1 Description/Mechanism of Droxidopa is a synthetic amino acid analog that is metabolized by dopa- Action decarboxylase to norepinephrine. Norepinephrine increases blood pressure through peripheral arterial and venous vasoconstriction. Indication(s) Under Review in Droxidopa is indicated for the treatment of orthostatic dizziness, this document lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been demonstrated. The continued effectiveness of droxidopa should be assessed periodically.1 Dosage Form(s) Under Droxidopa is available as 100 mg, 200 mg, 300 mg hard gelatin capsules. Review REMS REMS No REMS See Other Considerations for additional REMS information Pregnancy Rating Droxidopa is Pregnancy Category
    [Show full text]
  • Practical Approaches for the Treatment of Chronic Heart Failure: Frequently Asked Questions, Overlooked Points and Controversial Issues in Current Clinical Practice
    1 Practical approaches for the treatment of chronic heart failure: Frequently asked questions, overlooked points and controversial issues in current clinical practice Yüksel Çavuşoğlu, Hakan Altay1, Ahmet Ekmekçi2, Mehmet Eren2, Mehmet Serdar Küçükoğlu3, Sanem Nalbantgil4, İbrahim Sarı5, Timur Selçuk6, Ahmet Temizhan6, Dilek Ural7, Jean Marc Weinstein8, Dilek Yeşilbursa9, Mehmet Birhan Yılmaz10, Mehdi Zoghi4, Sinan Aydoğdu6, Merih Kutlu11, Necla Özer12, Mahmut Şahin13, Lale Tokgözoğlu12 Department of Cardiology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir-Turkey; 1Department of Cardiology, Faculty of Medicine, Başkent University, İstanbul-Turkey; 2Department of Cardiology, Siyami Ersek Hospital, İstanbul-Turkey; 3Department of Cardiology, İstanbul University, Cardiology Institute, İstanbul-Turkey; 4Department of Cardiology, Faculty of Medicine, Ege University, İzmir-Turkey; 5Department of Cardiology, Faculty of Medicine, Marmara University, İstanbul-Turkey; 6Department of Cardiology, Ankara Türkiye Yüksek İhtisas Hospital, Ankara-Turkey; 7Department of Cardiology, Faculty of Medicine, Kocaeli University, Kocaeli-Turkey; 8Department of Cardiology, Faculty of Medicine, Ben Gurion University, Bersheva-Israel; 9Department of Cardiology, Faculty of Medicine, Uludağ University, Bursa-Turkey; 10Department of Cardiology, Faculty of Medicine, Cumhuriyet University, Sivas-Turkey; 11Department of Cardiology, Faculty of Medicine, Karadeniz Teknik University, Trabzon-Turkey; 12Department of Cardiology, Faculty of Medicine, Hacettepe
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • Droxidopa (Northera®) EOCCO POLICY
    droxidopa (Northera®) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO122 Description Droxidopa (Northera®) is an orally administered synthetic amino acid analog that is metabolized to a norepinephrine by the enzyme aromatic L-amino acid decarboxylase (dopa-decarboxylase). Norepinephrine increases blood pressure by inducing peripheral arterial and venous vasoconstriction. Length of Authorization Initial: Three months Renewal: 12 months Quantity Limits Product Name Dosage Form Indication Quantity Limit 100 mg capsules 90 capsules /30 days droxidopa neurogenic orthostatic 200 mg capsules 180 capsules /30 days (Northera) hypotension (nOH) 300 mg capsules 180 capsules/30 days Initial Evaluation Generic droxidopa is the preferred agent. There is no prior authorization required for generic droxidopa, unless requesting above the quantity limit noted above. I. Brand droxidopa (Northera) may be considered medically necessary when the following criteria below are met: A. Member is 18 years of age or older; AND B. Medication is prescribed by, or in consultation with, a neurologist or cardiologist; AND C. A diagnosis of neurogenic orthostatic hypotension (nOH) when the following are met: 1. Member is experiencing one of the following symptoms: i. orthostatic dizziness ii. light-headedness iii. syncope; AND 2. Member has an additional diagnosis of: i. Primary autonomic failure (Parkinson disease, multiple system atrophy, or pure autonomic failure); OR 1 droxidopa (Northera®) EOCCO POLICY ii. Dopamine beta-hydroxylase deficiency; OR iii. Non-diabetic autonomic neuropathy; AND 3. Member has attempted at least one non-pharmacologic intervention (e.g., use of compression stockings/abdominal binder, increasing salt and fluid intake, regular exercise, or discontinuation or reduction of antihypertensive medications); AND 4.
    [Show full text]
  • Proamatine (Midodrine Hydrochloride)
    ProAmatine® (midodrine hydrochloride) Tablets Warning: Because ProAmatine® can cause marked elevation of supine blood pressure, it should be used in patients whose lives are considerably impaired despite standard clinical care. The indication for use of ProAmatine® in the treatment of symptomatic orthostatic hypotension is based primarily on a change in a surrogate marker of effectiveness, an increase in systolic blood pressure measured one minute after standing, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of ProAmatine®, principally improved ability to carry out activities of daily living, have not been verified. DESCRIPTION Name: ProAmatine® (midodrine hydrochloride) Tablets Dosage Form: 2.5-mg, 5-mg and 10-mg tablets for oral administration Active Ingredient: Midodrine hydrochloride, 2.5 mg, 5 mg and 10 mg Inactive Ingredients: Colloidal Silicone Dioxide NF, Corn Starch NF, FD&C Blue No. 2 Lake (10-mg tablets), FD&C Yellow No. 6 Lake (5-mg tablet), Magnesium Stearate NF, Microcrystalline Cellulose NF, Talc USP Pharmacological Classification: Vasopressor/Antihypotensive Chemical Names (USAN: Midodrine Hydrochloride): (1) Acetamide, 2-amino-N-[2-(2,5­ dimethoxyphenyl)-2-hydroxyethyl]-monohydrochloride, (±)-; (2) (±)-2-amino-N-(ß-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride BAN, INN, JAN: Midodrine Structural formula: Molecular formula: C12H18N2O4HCl; Molecular Weight: 290.7 Organoleptic Properties: Odorless, white, crystalline powder Solubility: Water: Soluble Methanol: Sparingly soluble pKa: 7.8 (0.3% aqueous solution) pH: 3.5 to 5.5 (5% aqueous solution) Melting Range: 200 to 203°C CLINICAL PHARMACOLOGY ® Mechanism of Action: ProAmatine forms an active metabolite, desglymidodrine, that is an alpha1-agonist, and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
    [Show full text]
  • 2000 Dialysis of Drugs
    2000 Dialysis of Drugs PROVIDED AS AN EDUCATIONAL SERVICE BY AMGEN INC. I 2000 DIAL Dialysis of Drugs YSIS OF DRUGS Curtis A. Johnson, PharmD Member, Board of Directors Nephrology Pharmacy Associates Ann Arbor, Michigan and Professor of Pharmacy and Medicine University of Wisconsin-Madison Madison, Wisconsin William D. Simmons, RPh Senior Clinical Pharmacist Department of Pharmacy University of Wisconsin Hospital and Clinics Madison, Wisconsin SEE DISCLAIMER REGARDING USE OF THIS POCKET BOOK DISCLAIMER—These Dialysis of Drugs guidelines are offered as a general summary of information for pharmacists and other medical professionals. Inappropriate administration of drugs may involve serious medical risks to the patient which can only be identified by medical professionals. Depending on the circumstances, the risks can be serious and can include severe injury, including death. These guidelines cannot identify medical risks specific to an individual patient or recommend patient treatment. These guidelines are not to be used as a substitute for professional training. The absence of typographical errors is not guaranteed. Use of these guidelines indicates acknowledgement that neither Nephrology Pharmacy Associates, Inc. nor Amgen Inc. will be responsible for any loss or injury, including death, sustained in connection with or as a result of the use of these guidelines. Readers should consult the complete information available in the package insert for each agent indicated before prescribing medications. Guides such as this one can only draw from information available as of the date of publication. Neither Nephrology Pharmacy Associates, Inc. nor Amgen Inc. is under any obligation to update information contained herein. Future medical advances or product information may affect or change the information provided.
    [Show full text]
  • The Toxicology Investigators Consortium Case Registry—The 2019 Annual Report
    Journal of Medical Toxicology https://doi.org/10.1007/s13181-020-00810-7 ORIGINAL ARTICLE The Toxicology Investigators Consortium Case Registry—the 2019 Annual Report Meghan B. Spyres1,2 & Lynn A. Farrugia3 & A. Min Kang2,4 & Kim Aldy5,6 & Diane P. Calello7 & Sharan L. Campleman6 & Shao Li6 & Gillian A Beauchamp8 & Timothy Wiegand9 & Paul M. Wax5,6 & Jeffery Brent10 & On behalf of the Toxicology Investigators Consortium Study Group Received: 6 August 2020 /Revised: 21 August 2020 /Accepted: 21 August 2020 # American College of Medical Toxicology 2020 Abstract The Toxicology Investigators Consortium (ToxIC) Registry was established by the American College of Medical Toxicology (ACMT) in 2010. The Registry collects data from participating sites with the agreement that all bedside medical toxicology consultation will be entered. This tenth annual report summarizes the Registry’s 2019 data and activity with its additional 7177 cases. Cases were identified for inclusion in this report by a query of the ToxIC database for any case entered from 1 January to 31 December 2019. Detailed data was collected from these cases and aggregated to provide information which included demo- graphics, reason for medical toxicology evaluation, agent and agent class, clinical signs and symptoms, treatments and antidotes administered, mortality, and whether life support was withdrawn. 50.7% of cases were female, 48.5% were male, and 0.8% were transgender. Non-opioid analgesics was the most commonly reported agent class, followed by opioid and antidepressant classes. Acetaminophen was once again the most common agent reported. There were 91 fatalities, comprising 1.3% of all Registry cases. Major trends in demographics and exposure characteristics remained similar to past years’ reports.
    [Show full text]
  • Mar-Midodrine
    PRODUCT MONOGRAPH Pr MAR-MIDODRINE Midodrine Hydrochloride Tablets 2.5 mg and 5 mg Manufacturer’s Standard Vasopressor Marcan Pharmaceuticals Inc. Date of Preparation: 2 Gurdwara Road, Suite #112, June 16, 2020 Ottawa, ON, K2E 1A2 Submission Control No: 239625 Page 1 of 23 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 3 SUMMARY PRODUCT INFORMATION ..................................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................................... 3 CONTRAINDICATIONS ................................................................................................................ 4 WARNINGS AND PRECAUTIONS .............................................................................................. 4 ADVERSE REACTIONS ................................................................................................................ 6 DRUG INTERACTIONS ............................................................................................................... 12 DOSAGE AND ADMINISTRATION ........................................................................................... 12 OVERDOSAGE ............................................................................................................................. 13 ACTION AND CLINICAL PHARMACOLOGY ......................................................................... 14 STORAGE AND STABILITY .....................................................................................................
    [Show full text]